Testing a new drug called NLG802 with temozolomide in children with brain tumors that are growing
Official title: Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study is testing whether a new drug called NLG802 is safe for children with brain tumors when it is given with a chemotherapy drug called temozolomide.
Read our full plain-language summary
What the trial team says
This is a open label Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, in combination with temozolomide chemotherapy in children with primary brain tumors.
Key facts
- Registry number
- NCT07732413
- Stage of testing
- Phase 1
- Conditions studied
- Progressive Pediatric Brain Cancer
Where it is running
This trial lists 1 site.
-
Georgia
- Augusta University, Georgia Cancer Center (Augusta)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.